T his analysis of the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safety of ezetimibe 10 mg added to ongoing statin therapy in patients with diabetes, metabolic syndrome without diabetes, or neither disorder who had low-density lipoprotein cholesterol (LDL-C) levels exceeding National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) goals. After six weeks of treatment, ezetimibe added to statin reduced LDL-C in patients with diabetes by 28%, metabolic syndrome by 24%, or neither by 26%, compared with a 3% reduction for placebo for each group. In each group, more patients receiving ezetimibe plus statin reached LDL-C goal (67-74%) compared with those receiving placebo plus statin (19-22%). Other parameters demonstrating greater improvement with ezetimibe included triglycerides, apolipoprotein (Apo)B/Apo A-I ratio, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein. Ezetimibe plus statin was well tolerated in each group. Ezetimibe added to ongoing statin therapy offers a new treatment option that is consistently effective in improvement of lipid profiles and attainment of LDL-C goals in patients with or without diabetes or metabolic syndrome. Diabetes Vasc Dis Res 2006;3:93-102
Introduction
Patients with type 2 diabetes mellitus (DM) and the metabolic syndrome (Met S) are at increased risk for the development of coronary heart disease (CHD) and cardiovascular disorders, 1,2 and for mortality from CHD. 3, 4 Lipid abnormalities contribute significantly to that increased risk. [5] [6] [7] [8] Numerous trials demonstrate the benefit of aggressive lowering of low-density lipoprotein cholesterol (LDL-C) with statin use on morbidity and mortality in patients at risk for CHD. [9] [10] [11] [12] Even those high-risk patients with normal to low levels of LDL-C benefit from this type of LDL-C lowering, as was shown for the nearly 6,000 patients with diabetes who were enrolled in the Heart Protection Study (HPS). 10 The Third Report of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) established diabetes as a CHD risk equivalent and recommended an LDL-C goal of < 2.6 mmol/L (< 100 mg/dL) for these patients. 13 Met S, as defined by NCEP ATP III, is associated with a clustering of at least three of the following risk factors: abdominal obesity, hypertension, impaired fasting glucose, high triglycerides, or a low level of high-density lipoprotein cholesterol (HDL-C) (a detailed definition is provided in the Methods section). High triglycerides (TG) and low HDL-C, together with the presence of small, dense, atherogenic LDL-C particles, form what is referred to as atherogenic dyslipidaemia. The additive risk conferred by these factors places most patients with Met S in the moderate-risk category for CHD, with a corresponding NCEP ATP III LDL-C goal of < 3.4 mmol/L (< 130 mg/dL). 13 Achieving the NCEP ATP III LDL-C goal in patients with diabetes or Met S typically requires statin therapy. [13] [14] [15] [16] However, many patients fail to achieve their LDL-C goals because of a failure to titrate adequately or because of poor patient compliance. [17] [18] [19] [20] The combination of the new agent, ezetimibe, plus a statin has the potential to lower LDL-C effectively by two independent and complementary path-ways: inhibition of cholesterol absorption by ezetimibe, [21] [22] [23] [24] and inhibition of cholesterol synthesis. For patients with diabetes or Met S, who require aggressive lipid-lowering therapy, this combination may offer an attractive therapeutic option.
Given the high prevalence of DM and Met S and the increased risk of CHD in these patients, 16, 25 it is important to assess lipid-lowering therapies in these patient populations. We present here a post-hoc analysis of patients with type 2 DM, Met S or neither disorder who were included in the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial. 26 This community practice-based, placebo-controlled, multicentre, six-week trial was conducted using hypercholesterolaemic patients (n=3,030) who were taking a statin but were not at their NCEP ATP III LDL-C goal. In the main study, the addition of ezetimibe to ongoing statin therapy provided significant additional improvements in lipid profile and LDL-C goal attainment and was well tolerated. The aim of these post-hoc analyses was to assess the effectiveness of adding ezetimibe 10 mg daily compared with placebo to the current statin therapy of patients with DM, Met S or neither by assessing LDL-C lowering, LDL-C goal attainment, improvements in other lipid measures and levels of high-sensitivity C-reactive protein (CRP).
Methods

Patients
Patients were recruited from 299 community-based practices across the United States from January 2003 to August 2003. Patients were eligible if they were more than 18 years old, were taking a stable, approved dose of any statin, had been following a cholesterol-lowering diet for at least six weeks prior to study entry, and met all key inclusion criteria. At screening, plasma LDL-C levels on statin therapy were required to be greater than the NCEP ATP III goal, as determined by the patient's risk category using NCEP ATP III criteria. All triglyceride levels had to be ≤ 4.0 mmol/L (350 mg/dL) to allow for LDL-C calculation by the Friedewald equation. 27 The research protocol was approved by the investigational review boards at each site, and all participants provided written informed consent to participate in the study.
Key exclusion criteria were a history, within three months of study entry, of acute coronary insufficiency (that is, unstable angina), myocardial infarction, stroke, surgical coronary intervention or other major vascular surgery procedures; untreated hypothyroidism or hyperthyroidism; untreated uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic > 100 mmHg); impaired renal function (creatinine > 176.8 µmol/L [2.0 mg/dL]); active liver disease; a history of statin-induced myopathy; uncontrolled diabetes mellitus (HbA 1C > 9% in patients with diabetes); or any medical condition that the investigator determined could limit a patient's evaluation or participation. Prohibited concomitant medications included lipid-altering agents other than statins, oral corticosteroids, and medications that were inconsistent with labelling for a patient's given statin.
Patients were considered to have DM if either it was listed on their medical history or they were taking diabetic medication. Patients were considered to have Met S (based on NCEP ATP III criteria) 13 if they had three or more of the following five characteristics: waist circumference > 102 cm (40 inches) in men or > 89 cm (35 inches) in women; TG > 1.7 mmol/L (150 mg/dL); HDL-C < 1.0 mmol/L (40 mg/dL) in men, < 1.3 mmol/L (50 mg/dL) in women; hypertension (BP > 130/85 mmHg or on antihypertensive medication); fasting glucose > 6.1 mmol/L (110 mg/dL); or a history of diabetes.
Study design
This multicentre, randomised, double-blind, placebo-controlled, six-week, parallel-group study (protocol # 040) included a screening phase one week prior to the baseline visit, followed by six weeks of treatment. More detailed information on this study has been published. 26 Briefly, patients were randomised, using an Interactive Voice Response System, 2:1 to either ezetimibe 10 mg or placebo, in addition to their current statin therapy and dose. The statin brand and dose were to be maintained throughout the study.
Blood specimens were collected at Visit 1 (eligibility), Visit 2 (blinded baseline lipids and CRP) and Visit 3 (blinded final lipid measures and CRP). All blood samples for lipid assessment were obtained after a fast of at least 12 hours. Investigators were not blinded to safety laboratory results. Safety evaluations included physical examination, vital signs, monitoring for adverse events, and routine laboratory evaluations, including serum creatine kinase (CK) and the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Laboratory methods
Medical Research Laboratories (Highland Heights, Kentucky), a laboratory certified by the National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention, performed the clinical laboratory analyses. Plasma cholesterol and TG levels were determined using enzymatic methods. HDL-C was measured after precipitation of the apolipoprotein B-containing lipoproteins (LDL-C and very low density lipoprotein [VLDL]) in whole plasma by heparin-manganese chloride. LDL-C was calculated by the method of the Friedewald equation. 27 High-sensitivity (HS)-CRP was measured by the immunonephelometric method (Dade Behring, Inc., Deerfield, Illinois, USA).
Statistical analysis
A modified intent-to-treat (MITT) population, which included all randomised patients with a baseline assessment and at least one valid post-baseline assessment of LDL-C, was used for the efficacy analyses. All patients who received study drug were included in the safety analyses. In addition, we performed efficacy analyses restricted to those patients who had CHD or were CHD risk equivalent (high-risk patients).
We analysed mean percentage changes from baseline in LDL-C, HDL-C, total C, non-HDL-C and Apolipoprotein B/Apolipoprotein A-I (Apo B/Apo A-I) ratio after six weeks of treatment, using an analysis of variance (ANOVA) model with terms for treatment, NCEP ATP III risk category, and percentage above LDL-C goal at screening (< 8%, > 8% to < 18%, > 18% to < 30%, or > 30%), subgroup, and the interaction of treatment and subgroup. For TG, the ANOVA model was analysed using normal scores rank-transformation of percentage change from baseline and statistical inferences were based on the non-parametric results. Because patients with DM had an LDL-C treatment goal of < 100 mg/dL (< 2.6 mmol/L), they were more likely to have a lower mean baseline LDL-C level than that of patients not considered to be in the CHD or CHD risk-equivalent category. Thus, we also performed analyses that were restricted to CHD or CHD risk-equivalent patients in the Met S and neither subgroups to compare patients with the same LDL-C treatment goal.
The percentage of patients reaching NCEP ATP III LDL-C goal (< 2.6 mmol/L [< 100 mg/dL] for patients with CHD or CHD risk equivalent, < 3.4 mmol/L [< 130 mg/dL] for patients with > 2 CHD risk factors conferring a 10-year risk of CHD < 20%, and < 4.1 mmol/L [< 160 mg/dL] for patients with < 2 CHD risk factors) after six weeks of treatment was analysed using a logistic regression model with terms for treatment, NCEP ATP III risk category, percentage above LDL-C goal at Visit 1, subgroup (DM, Met S or neither), and the interaction of treatment and subgroup. Because a patient's LDL-C level for determination of eligibility was measured at screening, with baseline LDL-C measured at randomisation one week later, it was possible for a patient to be at goal at baseline. These analyses excluded patients who were at goal at baseline.
Post-hoc analyses of high-sensitivity CRP were performed on archived serum samples from patients for whom both a valid baseline and one post-baseline value were available. Because the distribution of CRP measurements is skewed, the above ANOVA model was analysed with rank transformed values (using Tukey normal scores). Medians and 95% confidence intervals for the medians are presented.
Results
Patient accounting
A total of 5,802 patients were screened at baseline for the EASE study. Of these, 2,772 were excluded, the majority because they were found to be at NCEP ATP III target LDL-C level. The remaining 3,030 eligible patients were randomised at 299 US sites: 2,020 received ezetimibe 10 mg in addition to their current statin therapy and 1,010 received placebo in addition to their current statin treatment. Twelve patients did not receive double-blind study medication. The complete flow of patients through the study can be found in the publication describing the overall EASE study. 26 
Patient characteristics at baseline
Patient characteristics at baseline for the DM, Met S and neither subgroups are shown in table 1. The prevalence of these three conditions was similar between the treatment groups (table 1). White patients were predominant in all subgroups. The percentage of black patients with DM (13%) was higher than the percentages of black patients with Met S or neither disorder (6% and 8%, respectively). Overall, patients with DM or Met S had higher body mass indices (33 and 31 kg/m 2 , respectively), consistent with obesity, compared with patients with neither disorder (28 kg/m 2 ). Similarly, a greater proportion of patients with DM or Met S had waist circumferences characteristic of Met S (> 88 cm in women, > 102 cm in men), indicating a greater preponderance of abdominal obesity in these populations. Patients with DM or Met S were fairly evenly divided between the sexes (49% and 47% men, respectively), while patients with neither disorder were more likely to be men (60%). Patients with DM had a more favourable baseline lipid profile (lower LDL-C, TG, non-HDL-C, total C, Apo B/Apo A-I ratio and CRP; higher HDL-C) compared with patients with Met S (table 2), consistent with the lower target goals for the DM patients and more aggressive therapy. In the DM subgroup, 58% were using one oral antidiabetic medication; 33% were using thiazolidinediones.
All available marketed brands and doses of statins were represented in the trial (table 3) . Rosuvastatin was not marketed at the time of this study. In patients with DM or Met S, atorvastatin was the statin most commonly used (39% and 42%, respectively), followed by simvastatin (29%, 27%) and pravastatin (22%, 22%). The distribution of statins and doses was similar in patients with DM or Met S compared to those with neither condition (table 3) , and also comparable to the overall population. 26 Efficacy LDL-C and additional lipid parameters The addition of ezetimibe to ongoing statin therapy, compared with the addition of placebo, resulted in significant (p<0.001) reductions in LDL-C (table 2). The addition of ezetimibe reduced LDL-C by 27.8% in patients with DM and by 24.3% in patients with Met S, compared with 2.9% and 2.8% reductions for patients with DM and Met S, respectively, who were treated with the addition of placebo to ongoing statin therapy. In the subset of patients with neither DM nor Met S, the addition of ezetimibe to statin therapy significantly reduced LDL-C by an additional 22.4% beyond placebo (p<0.001). Treatment effects were consistent for LDL-C lowering across patients with DM, Met S or neither disorder.
Additional lipid parameters, TG, HDL-C (except for the neither disorder subgroup), non-HDL-C, total C and Apo B/Apo A-I ratio, and CRP (except for the Met S subgroup) also improved significantly and consistently (p>0.05 for all treatment by subgroup interactions) when ezetimibe was added to statin therapy in patients with DM, Met S or neither disorder compared with the addition of placebo (table 2) .
We also examined the efficacy of ezetimibe added to statin therapy in CHD or CHD risk-equivalent patients within these subgroups, to compare efficacy among those patients with the lowest LDL-C goal (<100 mg/dL [2.6 mmol/L]) and who potentially were receiving the most aggressive treatment. CHD or CHD risk-equivalent patients with DM had a qualitatively better overall lipid profile at baseline than those with Met S (table 4) . Ezetimibe, when added to statin therapy, provided significant improvements in the lipid profile of the high-risk patients with DM and Met S (table 4). Treatment effects were consistent among the high-risk populations we analysed, and they were comparable to those of the overall MITT population.
LDL-C goal attainment
Goal attainment was analysed in those patients who were not at goal at baseline. Within each subgroup of DM, Met S or neither, significantly more patients who received ezetimibe in addition to statin reached their NCEP ATP III LDL-C goal, compared with patients who received placebo in addition to statin (p <0.001). In the patient groups with DM or Met S, 71.1% and 67.1%, respectively, attained their goal when ezetimibe was added to their statin, compared with 21.1% and 21.9% of patients treated with placebo added to statin. In the patients who had neither disorder, 74.3% attained goal when ezetimibe was added to their statin, compared with 19.0% for patients treated with placebo plus statin. Treatment effects were consistent in patients with DM, Met S or neither disorder (treatment by DM/Met S/neither interaction was not statistically significant).
For the CHD and CHD risk-equivalent patients not at goal at baseline who had DM, Met S or neither, 70.9%, 63.1% and 72.6%, respectively, attained NCEP ATP III LDL-C goals when ezetimibe was added to their statin therapy, compared with 21.3%, 15.7% and 12.0%, respectively, of the patients treated with placebo plus statin. All of the additional increases in the percentages of patients reaching their NCEP ATP III LDL-C goals obtained by adding ezetimibe, compared with adding placebo, were statistically significant (p<0.001).
Apolipoprotein B/Apolipoprotein A-I ratio
The addition of ezetimibe to ongoing statin therapy, compared with the addition of placebo, significantly (p<0.001) reduced the apolipoprotein B/apolipoprotein A-I ratio in patients with DM or Met S, or in patients with neither disorder, resulting in additional between-treatment reductions of 17.7%, 16.6% and 15.1%, respectively (table 2) .
High-sensitivity C-reactive protein At baseline, patients with DM or Met S had higher median ORIGINAL ARTICLE CRP levels than patients with neither disorder (table 2) . Patients with DM who were treated with ezetimibe added to statin showed a 12.0% reduction in CRP from baseline compared with a 0.0% change for placebo-treated DM patients.
Patients with Met S in whom ezetimibe was added to statin therapy showed an 11.0% reduction in CRP from baseline compared with a 4.3% change for placebo-treated Met S patients. Patients with neither DM nor Met S who were treated with ezetimibe added to statin showed a 13.0% reduction in CRP from baseline compared with a 3.7% reduction for placebo-treated patients in this subgroup. The addition of ezetimibe to ongoing statin therapy produced a significant ORIGINAL ARTICLE (p<0.001) reduction in CRP across the DM/Met S/neither subgroups. There was no statistically significant interaction between treatment and subgroup (DM, Met S or neither; p=0.199). The improvement in CRP levels seen after the addition of ezetimibe to ongoing statin therapy was consistent across patients with DM, Met S or neither disorder.
In the CRP analysis restricted to CHD or CHD riskequivalent patients, patients with DM or Met S had higher median baseline CRP levels than those with neither disorder (table 4) . Patients with DM, Met S or neither who were treated with ezetimibe added to statin therapy had reductions from baseline levels of 12.1%, 10.0% and 15.8%, respectively, compared with a 0.0% reduction for placebotreated patients in all three subgroups. The addition of ezetimibe to ongoing statin therapy produced a significant (p<0.001) reduction in CRP across the DM/Met S/neither subgroups. There was no statistically significant interaction between treatment and subgroup (DM, Met S or neither; p=0.433): therefore, the improvement in CRP levels seen after the addition of ezetimibe to ongoing statin therapy was consistent across patients with DM, Met S or neither disorder.
Safety and tolerability
The safety and tolerability findings when ezetimibe is added to statin therapy, compared with placebo added to statin, for the overall EASE trial have been published previously. 26 Briefly, drug-related clinical adverse events occurred in 5.2% of the placebo plus statin-treated patients and 5.1% of the ezetimibe plus statin-treated patients. Drug-related clinical adverse events that led to study drug discontinuation occurred in 1.6% of the placebo plus statin group and 0.9% of the ezetimibe plus statin group. None of the drug-related clinical adverse events were considered serious, and no deaths were reported during the study.
The occurrence of drug-related laboratory adverse events was similar between the treatment groups and is shown in table 5. None of these events were considered serious, and discontinuations as a result of a laboratory adverse event did not occur. There were no significant dif-ORIGINAL ARTICLE ferences between the treatment groups in either the percentage of patients who exceeded pre-defined limits of change in liver transaminases (ALT and AST), or in muscle CK (table 5 ). There were no other clinically important differences between the treatment groups in the results of laboratory tests or clinical safety assessments.
Discussion
There are numerous studies demonstrating that lowering LDL-C in high-risk patients with hypercholesterolaemia decreases cardiovascular morbidity and mortality. 9, 10, 12, [28] [29] [30] [31] [32] Evidence indicates a strong association of increased LDL-C concentrations with coronary artery disease in patients at risk, and suggests that an aggressive lipid-lowering strategy is needed in these patients. 7, 9, 33 Several studies have also shown that LDL-C lowering with statins in patients with DM significantly reduced the risk of cardiovascular events. 25, 34 The Heart Protection Study demonstrated that, following treatment with simvastatin, the patients with diabetes without a previous history of CHD or high cholesterol benefited by a ORIGINAL ARTICLE one-third reduction in the incidence of coronary events. 10 Furthermore, the Collaborative Atorvastatin Diabetes Study (CARDS) demonstrated that treatment with atorvastatin of patients with diabetes with no history of cardiovascular disease and without high levels of LDL-C was associated with a decreased risk of major cardiovascular events. 35 All patients with DM are considered at high risk for CHD, while patients with Met S are likely to fall into either the moderate-or high-risk category, depending on their particular constellation of risk factors. Several definitions of Met S by national and multinational organisations have been published. 13, [36] [37] [38] [39] The definitions have several commonalities, with inclusion in each of obesity, glucose intolerance, dyslipidaemia and hypertension among factors that characterise Met S. In this study, the NCEP ATP III definition of Met S 13 was utilised because it is widely accepted and applied. NCEP ATP III recommends LDL-C goals < 2.6 mmol/L (< 100 mg/dL) for patients at high risk for CHD and LDL-C goals < 3.4 mmol/L (< 130 mg/dL) for patients considered to be at moderate risk. Lower levels of LDL-C have been recommended as optional goals. 14 However, many patients with DM are not treated to their optimal LDL-C and lipid levels, despite the widespread availability and use of statins. [40] [41] [42] In addition to setting aggressive LDL-C-lowering goals for all high-risk patients, including those with DM, targets for other lipid abnormalities associated with DM have been established. 13 Type 2 DM, along with insulin resistance and Met S, is associated with an atherogenic lipoprotein profile 43 characterised by elevated levels of plasma TG, reduced HDL-C and small, dense, atherogenic LDL-C particles. 6, [44] [45] [46] This atherogenic dyslipidaemia, termed diabetic dyslipidaemia in patients with DM, 6, 13, 47, 48 contains two components (elevated TG and small, dense LDL-C particles) that have been identified as emerging cardiovascular risk factors in all patients, but especially in patients with DM. 13 As a result, both the American Diabetes Association 49 and the NCEP ATP III guidelines 13 indicate that in addition to an LDL-C goal of < 2.6 mmol/L (< 100 mg/dL), optimal HDL-C levels should be > 1.0 mmol/L (40 mg/dL) in men, > 1.3 mmol/L (50 mg/dL) in women, and TG levels should be < 1.7 mmol/L (< 150 mg/dL) in patients with DM.
A recent update to the NCEP ATP III guidelines 14 suggests that even more aggressive LDL-C lowering to < 1.8 mmol/L (< 70 mg/dL) or < 2.6 mmol/L (< 100 mg/dL) be considered in high-risk and moderate-risk populations, respectively. The more aggressive LDL-C goal of < 1.8 mmol/L was confirmed in recent guidelines of the American Heart Association and American College of Cardiology for secondary prevention in patients with atherosclerotic vascular disease. 50 Treatment of atherogenic dyslipidaemia involves treatment of the individual lipid abnormalities. Lifestyle modification, including dietary modification, weight management and an increase in physical activity, should be implemented first. 13 However, if these lipid abnormalities persist after lifestyle modifications, then pharmacological intervention should be considered. A recent update of the NCEP ATP III guidelines 14 recommends that in high-risk patients (including those with DM) with high levels of TG or low levels of HDL-C, combining a LDL-C-lowering drug with a compound to lower TG and raise HDL-C should be considered. Ezetimibe, a potent inhibitor of cholesterol absorption from the intestines, [22] [23] [24] either alone 51 or in combination with a statin [52] [53] [54] has been shown not only to reduce plasma LDL-C levels significantly in patients with hypercholesterolaemia, but also to reduce TG levels significantly and to increase HDL-C levels significantly. Thus, the results of previous clinical trials [51] [52] [53] [54] suggest that ezetimibe added to a statin, as combination therapy, offers the potential to be an effective treatment option in the lipid management of the atherogenic dyslipidaemia frequently found in patients with DM or Met S.
The EASE study examined the effectiveness of ezetimibe 10 mg daily added to ongoing statin therapy in patients from community-based practices. The addition of ezetimibe to ongoing statin therapy significantly reduced LDL-C levels and improved goal attainment, as well as significantly improving other lipid parameters (such as TG, HDL-C, non-HDL-C and apo B) in the overall population. The addition of ezetimibe to ongoing statin therapy was also well tolerated. 26 The EASE trial included a substantial number of patients with DM and Met S. Adding ezetimibe 10 mg daily to the patient's existing statin brand and dose for six weeks resulted in statistically significant 24% and 28% mean reductions in LDL-C in patients with DM or Met S, respectively, compared with adding placebo (which resulted in a 3% reduction). Treatment with ezetimibe added to these patients' ongoing statin therapy also significantly improved other aspects of the lipid profile (such as TG, HDL-C, non-HDL-C, total C and Apo B/Apo A-I ratio) and resulted in consistent treatment effects across these groups, despite the differing lipid levels of these patient groups at baseline (table 2) . Finally, the addition of ezetimibe to statin therapy resulted in ORIGINAL ARTICLE followed by a measurement < 3xULN that was taken more than two days after the last dose of study medication.
an additional 50% and 45% of DM and Met S patients, respectively, attaining their LDL-C goal. These improvements in the lipid profile overall were consistent with those for patients who had neither of these disorders. It is notable that patients with DM on statin therapy appeared to have lower baseline LDL-C levels compared with patients with Met S or neither disorder. This suggests that patients with DM may have been receiving more aggressive lipid-lowering treatment than the other patients. The oral diabetic medications these patients were using may also have contributed, as some of these medications (e.g. the thiazolidinediones) can alter certain lipid parameters. 55 The treatment effects were also consistent across the subgroups of DM, Met S and neither disorder when the analyses were restricted to those patients who were considered to be at high risk (CHD or CHD risk-equivalent), that is, patients with the most aggressive treatment goals. The highrisk patients with DM, Met S or neither disorder benefited similarly in terms of attaining additional significant improvements in LDL-C lowering and LDL-C goal attainment, as well as improvement in the lipid profiles (e.g. TG, non-HDL-C and total C), following treatment with ezetimibe added to their ongoing statin therapy. This demonstrates that patients with equivalent treatment goals (LDL-C < 2.6 mmol/L [< 100 mg/dL]) benefited from the addition of ezetimibe to their ongoing statin therapy, regardless of the underlying metabolic disorder.
The apo B/apo A-I ratio has been shown to be predictive of cardiovascular risk 29, [56] [57] [58] [59] [60] [61] [62] [63] and is emerging as an important treatment consideration. 61 In our study, this ratio was highest at baseline in patients with Met S, and was lower by comparison in patients with DM or patients with neither disorder. Ezetimibe added to statin significantly improved this ratio in all subgroups by reducing this ratio an additional 15% to 18%.
The results of these post-hoc analyses from the EASE study are also generally consistent with other studies that have examined the effects of ezetimibe in combination with simvastatin or ongoing statin therapy [64] [65] [66] [67] in patients with DM or Met S.
Ezetimibe was well tolerated. The safety of ezetimibe added to ongoing statin therapy, based on the results of clinical and laboratory assessments, was comparable to that of placebo added to statin.
Ezetimibe, 10 mg/day, in combination with a statin, offers an effective therapy for hypercholesterolaemic patients with DM or Met S. Ezetimibe can be added to several brands of statin at a variety of doses to improve LDL-C lowering and goal attainment significantly in these patients. Ezetimibe, when added to statin therapy, provided additional benefits to other lipid parameters, including TG, HDL-C, non-HDL-C, total C and the apo B/A-I ratio, as well as CRP. These results suggest that ezetimibe offers an effective treatment option for patients with DM or Met S and improves goal attainment in these populations with aggressive target lipid goals.
